Cisplatin-vinorelbine chemotherapy in non-small cell lung cancer is safe and well tolerated: Results of a retrospective Hungarian clinical data analysis

Expert Opinion on Drug Safety

Volumn 8, Issue 1, 2009, Pages 9-14

  Szilasi, Mária ^b   Müller, Veronika ^a   Juhász, Erzsébet ^c   Magyar, Pál ^a   Budai, Marianna ^a   Tamási, Lilla ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c National Korányi Tuberculosis and Lung Disease   (Hungary)

Author keywords

Cisplatin vinorelbine chemotherapy; Non small cell lung cancer; Quality of life; Retrospective data analysis; Safety; Tolerability

Indexed keywords

CISPLATIN; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DATA ANALYSIS; DETERIORATION; DIARRHEA; DRUG EFFECT; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRANULOCYTE; HUMAN; HUNGARY; LABORATORY TEST; LEUKOCYTE COUNT; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MEDICAL RECORD REVIEW; NAUSEA; PATIENT ASSESSMENT; QUALITY OF LIFE; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; THROMBOCYTE COUNT; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; HUNGARY; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE;

EID: 67649446282     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802521771     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96
2. Farjah F, Wood DE, Yanez D III, et al. Temporal trends in the management of potentially resectable lung cancer. Ann Thorac Surg 2008;85(6):1850-1855 (Pubitemid 351685592)
3. Ponn RB, Cicero J III, Daly BDT. Surgical treatment of nonsmall cell lung cancer. In: Shields TW, Lo Cicero, Ponn R, et al, editors. General thoracic surgery. 6th edition. Philadelphia: Lippincott Williams and Wilkins 2005;1548-1587
4. Scott WJ, Howington J, Feigenberg S, et al. American College of Chest Physicians. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines 2nd edition. Chest 2007;132:234-242
5. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin vs. vindesine and cisplatine vs. vinorelbine alone in advanced non-small cell lung cancer: result of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-367 (Pubitemid 24983442)
6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: non-small cell lung cancer. V.2.2008. Available from: www.nccn.org [Last accessed 29 June 2008]
7. Winton T, Livingston R, Johnson D, et al. National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatine vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597
8. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007;25:1545-1552 (Pubitemid 46733081)
9. Gridelli C, Maione P, Rossi A, et al. Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 2006;17:72-78 (Pubitemid 43985210)
10. Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. Eur J Cancer 1997;33:392-397 (Pubitemid 27168064)
11. Costa GJ, Fernandes AL, Pereira JR, et al. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC). Lung Cancer 2006;53:171-176 (Pubitemid 43994228)
12. Ostoros G, Szondy K, Gergely-Farnos E, et al. Efficacy of gemcitabine-cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer. Anticancer Res 2005;25:471-475 (Pubitemid 40470052)
13. Dimitroulis J, Toubis M, Antoniou D, et al. Alternate paclitaxel-gemcitabine and paclitaxel-vinorelbine biweekly administration in non-small cell lung cancer patients: a Phase II study. Anticancer Res 2006;26:1397-1402
14. Ohe Y, Ohashi Y, Kubota K, et al. Randomized Phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-323 (Pubitemid 46323100)
15. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised Phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005;41:81-92 (Pubitemid 40029660)
16. Survelliance, Epidemiology, and End Results (SEER): cancer statistics review 1975-2004, National Cancer Institute. Bethesda, MD. Available from: www.seer.cancer.gov/csr/1975-2004 [Last accessed 29 June 2008]
17. Chen YM, Perng RP, Shih JF, Whang-Peng J. A Phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. 2008;61(2):214-219 Epub 2008 Feb 19
18. Gridelli C, Maione P, Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol 2007;25:4663-4669 (Pubitemid 350035327)
19. Früh M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008;26:3573-3581
20. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7(9):719-727 (Pubitemid 44283661)